<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03998826</url>
  </required_header>
  <id_info>
    <org_study_id>CEBD-CU-2019-06-13</org_study_id>
    <nct_id>NCT03998826</nct_id>
  </id_info>
  <brief_title>Piroxicam Premedication for Postendodontic Pain in Non-vital Mandibular Molars</brief_title>
  <official_title>Effect of Piroxicam Premedication on Postendodontic Pain in Mandibular Molars With Non-vital Pulp: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the effect of piroxicam (20mg) compared to placebo on
      post-endodontic pain of single-visit endodontic treatment of non-vital mandibular molars.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Patients will be clinically and radiographically examined and their eligibility will be
           assessed. Eligible patients will be treated in one visit.

        -  Patients will be randomly assigned to one of 2 groups: experimental group (premedication
           with 20 mg of piroxicam) and the control group (premedication with placebo). Each
           participant will receive a standard inferior alveolar nerve block injection. After
           endodontic treatment, patients will be given postoperative instructions and informed, in
           case of pain, to receive ibuprofen 200 mg as rescue medication.

        -  Postendodontic pain intensity and incidence at the different pain categories (No, mild,
           moderate, severe) will be assessed 6, 12, 24, 48, 72 hours and 7 days postoperatively
           using a 0-10 numerical rate scale (NRS). Analgesic intake throughout the 7 days will be
           recorded.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment Type: Two arm, parallel, randomized clinical trial. Allocation ratio: 1:1 Framework: Superiority.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The study will be participant and operator-blind where the participant and operator will not know the intervention done.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Postendodontic pain using a pain-measuring scale</measure>
    <time_frame>6 hours</time_frame>
    <description>Postoperative pain is measured using the Numerical Rating Scale (NRS) which is an 11-point scale from 0-10 where 0 represents no pain and 10 represents the worst pain measured 6 hours after the first visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postendodontic pain using a pain-measuring scale</measure>
    <time_frame>12 hours</time_frame>
    <description>Postoperative pain is measured using the Numerical Rating Scale (NRS) which is an 11-point scale from 0-10 where 0 represents no pain and 10 represents the worst pain measured 12 hours after the first visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postendodontic pain using a pain-measuring scale</measure>
    <time_frame>24 hours</time_frame>
    <description>Postoperative pain is measured using the Numerical Rating Scale (NRS) which is an 11-point scale from 0-10 where 0 represents no pain and 10 represents the worst pain measured 24 hours after the first visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postendodontic pain using a pain-measuring scale</measure>
    <time_frame>48 hours</time_frame>
    <description>Postoperative pain is measured using the Numerical Rating Scale (NRS) which is an 11-point scale from 0-10 where 0 represents no pain and 10 represents the worst pain measured 48 hours after the first visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postendodontic pain using a pain-measuring scale</measure>
    <time_frame>72 hours</time_frame>
    <description>Postoperative pain is measured using the Numerical Rating Scale (NRS) which is an 11-point scale from 0-10 where 0 represents no pain and 10 represents the worst pain measured 72 hours after the first visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postendodontic pain using a pain-measuring scale</measure>
    <time_frame>7 days</time_frame>
    <description>Postoperative pain is measured using the Numerical Rating Scale (NRS) which is an 11-point scale from 0-10 where 0 represents no pain and 10 represents the worst pain measured 7 days after the first visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analgesic medication intake incidence</measure>
    <time_frame>7 days</time_frame>
    <description>Analgesic medication intake incidence (Yes/No) as a rescue medication in case postoperative pain persisted after the sham medication intake.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non-Vital Tooth</condition>
  <arm_group>
    <arm_group_label>Piroxicam drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg piroxicam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piroxicam</intervention_name>
    <description>20mg piroxicam</description>
    <arm_group_label>Piroxicam drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aging between 18-50 years old

          2. Patients with mandibular molar with non-vital pulp.

          3. Systemically- healthy patients (ASA I or II).

          4. Patients who agree to attend for recall appointments and provide a written consent.

        Exclusion Criteria:

          1. Pregnant or lactating female patients.

          2. Patients allergic to piroxicam.

          3. History of peptic ulceration.

          4. Periapical abscess, fistula.

          5. Non-restorable teeth.

          6. Moderate or severe marginal periodontitis i.e. pocket probe&gt;3mm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asmaa FE Mohamed, B.D.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>faculty of dentistry Cairo university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Asmaa FE Mhamed, B.D.S</last_name>
    <phone>+201273035494</phone>
    <email>logainali89@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suzan AW Amin, Ph.D</last_name>
    <email>swaness@rocketmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Konagala RK, Mandava J, Pabbati RK, Anupreeta A, Borugadda R, Ravi R. Effect of pretreatment medication on postendodontic pain: A double-blind, placebo-controlled study. J Conserv Dent. 2019 Jan-Feb;22(1):54-58. doi: 10.4103/JCD.JCD_135_18.</citation>
    <PMID>30820083</PMID>
  </reference>
  <reference>
    <citation>Joshi N, Mathew S, George JV, Hegde S, Bhandi S, Madhu KS. Comparative evaluation of the efficacy of two modes of delivery of Piroxicam (Dolonex(Â®)) for the management of postendodontic pain: A randomized control trial. J Conserv Dent. 2016 Jul-Aug;19(4):301-5. doi: 10.4103/0972-0707.186454.</citation>
    <PMID>27563175</PMID>
  </reference>
  <reference>
    <citation>Nekoofar MH, Sadeghipanah M, Dehpour AR. Evaluation of meloxicam (A cox-2 inhibitor) for management of postoperative endodontic pain: a double-blind placebo-controlled study. J Endod. 2003 Oct;29(10):634-7.</citation>
    <PMID>14606784</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 25, 2019</study_first_submitted>
  <study_first_submitted_qc>June 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2019</study_first_posted>
  <last_update_submitted>July 13, 2019</last_update_submitted>
  <last_update_submitted_qc>July 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Asmaa Fathelrahman Mohamed</investigator_full_name>
    <investigator_title>Postgraduate Student, Department of Endodontics, Faculty of Dentistry, Cairo University</investigator_title>
  </responsible_party>
  <keyword>Piroxicam</keyword>
  <keyword>Postendodontic pain</keyword>
  <keyword>analgesic intake</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tooth, Nonvital</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Piroxicam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

